C4 Therapeutics, Inc. (CCCC) — Financial statements
Income statement, balance sheet, and cash flow for C4 Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 36↑1.0% | 36↑71.4% | 21↓33.3% | 31↓32.1% | 46 | |
| Cost of Revenue | 8 | 0.00↓100.0% | 8 | 0.00 | 0.00 | |
| Gross Profit | 28↓21.4% | 36↑173.3% | 13↓58.1% | 31↓32.1% | 46 | |
| Operating Expenses | ||||||
| R&D Expenses | 104↓5.8% | 111↓6.0% | 118↓0.1% | 118↑24.5% | 95 | |
| General & Administrative Expenses | 36↓14.1% | 42↑0.1% | 42↓1.7% | 43↑28.7% | 33 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 36↓14.1% | 42↑0.1% | 42↓1.7% | 43↑28.7% | 33 | |
| Other Expenses | -8↓427.2% | 2↑131.5% | -8 | 0.00 | 0.00 | |
| Operating Expenses | 132↓14.7% | 155↑2.1% | 152↓5.3% | 161↑25.6% | 128 | |
| Total Costs & Expenses | 140↓9.5% | 155↓2.9% | 160↓0.5% | 161↑25.6% | 128 | |
| Operating Results | ||||||
| Operating Income | -104↑12.6% | -120↑14.0% | -139↓7.3% | -130↓57.7% | -82 | |
| Depreciation & Amortization | 2↑7.8% | 2↓76.5% | 8↑361.6% | 2↑12.3% | 1 | |
| EBITDA | -103↑0.4% | -103↑15.3% | -122↑1.8% | -124↓54.9% | -80 | |
| EBIT | -105↑0.3% | -105↑19.0% | -130↓3.1% | -126↓54.1% | -82 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 14↑71.0% | 8↑521.0% | 1↑177.3% | -2 | |
| Interest Income | 0.00↓100.0% | 14↑47.1% | 10↑174.5% | 4↑823.8% | 0.39 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 1↓38.0% | 2↑3.3% | 2 | |
| Non-Operating Income | 0.38↑102.7% | -14↓57.0% | -9↓157.1% | -4↓823.8% | -0.39 | |
| Other Income / Expenses | -0.38↓102.7% | 14↑84.6% | 8↑475.3% | 1↑177.3% | -2 | |
| Income Before Tax | -105↑0.3% | -105↑19.8% | -131↓2.4% | -128↓52.8% | -84 | |
| Income Tax Expense | 0.12↓7.6% | 0.13↓89.8% | 1 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -105↑0.3% | -105↑20.5% | -132↓3.4% | -128↓52.8% | -84 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -105↑0.3% | -105↑20.5% | -132↓3.4% | -128↓52.8% | -84 | |
| Bottom-Line Net Income | -105↑0.3% | -105↑20.5% | -132↓3.4% | -128↓52.8% | -84 | |
| EPS (Basic) | -1.27↑16.4% | -1.52↑43.1% | -2.67↓1.9% | -2.62↓44.0% | -1.82 | |
| EPS (Diluted) | -1.27↑16.4% | -1.52↑43.1% | -2.67↓1.9% | -2.62↓44.0% | -1.82 | |
| Weighted Average Shares | 83↑19.5% | 69↑39.7% | 50↑1.6% | 49↑6.1% | 46 | |
| Weighted Average Diluted Shares | 83↑19.5% | 69↑39.7% | 50↑1.6% | 49↑6.1% | 46 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.